Core 2. Epidemiology and Prevention of CV Disease: Physiology, Pharmacology and LifestyleSession Title: Heart Failure, SCD and Medical Devices |
Abstract 12665: Real-World Comparison of 2-year Clinical Outcomes Between First Generation and Second Generation Drug-eluting Stents in Asian Population
Sang-Ho Park1; Seung Woon Rha2; A-Ra Cho3; Hyeok-Gyu Lee3; Se-Whan Lee3; Won-Yong Shin3; Seung-Jin Lee3; Dong-Kyu Jin3; Byoung Geol Choi2; Se Yeon Choi2; Amro Elnagar2; Sung Il Im2; SunWon Kim2; Jin Oh Na2; Seong Woo Han2; Cheol Ung Choi2; Hong Euy Lim2; Jin Won Kim2; Eung Ju Kim2; Chang Gyu Park2; Hong Seog Seo2; Dong Joo Oh21 Cardiovascular Cntr, Soonchunhyang Univ Cheonan Hosp, Cheonan, Korea, Republic of
2 Cardiovascular Cntr, Korea Univ Guro Hosp, Seoul, Korea, Republic of
3 Cardiology department, Soonchunhyang university cheonan hospital, cheonan, Korea, Republic of
Background: There have been few studies comparing the efficacy and safety of 1st and 2nd generation drug-eluting stents (DESs) and their 2-year clinical outcomes in real world clinical practice at all comer base specifically in Asian population.
Methods: A total 1,567 consecutive patients (pts) underwent percutaneous coronary intervention (PCI) with 1st & 2nd generation DESs between 2005 and 2009 were enrolled. We compared 6-month angiographic and 2-year major clinical outcomes of pts treated with 1st generation DESs [DES-1; sirolimus (n=527)- and paclitaxel (n=554)-eluting stents, n=1081)] versus 2nd generation DESs [DES-2; zotarolimus (n=371)- and everolimus (n=115)-eluting stents, n=486).
Results: Baseline characteristics were similar between the two groups except use of cilostazol, chronic renal insufficiency was higher and the total stent length was longer in the DES-1 group whereas diabetes mellitus was higher in the DES-2 group. At 6- month angiographic outcomes were similar between the two groups. Further, after adjustment of baseline confounders, major clinical outcomeswere similar between the two groups at 2-years (table).
Conclusions: In our study, mid-term angiographic and 2-year major clinical outcomes were similar between the first (sirolimus and paclitaxel) and second (zotarolimus and everolimus) generation DESs in all comer real world clinical practice in a series of Asian population.
Author Disclosures: S. Park: None. S. Rha: None. A. Cho: None. H. Lee: None.S. Lee: None. W. Shin: None. S. Lee: None. D. Jin: None. B. Choi: None. S. Choi: None. A. Elnagar: None. S. Im: None. S. Kim: None. J. Na: None. S. Han: None. C. Choi: None. H. Lim: None. J. Kim: None. E. Kim: None. C. Park: None. H. Seo: None. D. Oh: None.
Key Words: Drug eluting stents • Outcomes • Percutaneous coronary intervention
댓글 0